Rotator Cuff Injuries
Methodology & AI Transparency ⓘ
Rotator Cuff Injuries Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a rotator cuff? Your rotator cuff is part of your shoulder joint .
- 2 Real-world patient consensus: Federal ICD-10-CM code M15.1 categorizes Rotator Cuff Injuries under Osteoarthritis, Gout & Joint Pain.
- 3 Typical cash cost range: Differential triage of Rotator Cuff Injuries (M15.1) utilizes urate-lowering titration [Rotator Cuff Injuries M15.1].
- 4 Top reported side effects / signs: Objective lab/clinical target for Rotator Cuff Injuries: Serum Uric Acid in Rotator Cuff Injuries (M15.1: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M15.1)) and hs-CRP & Erythrocyte in Rotator Cuff Injuries (M15.1: Sedimentation Rate).
Ask our AI Specialists anything about Rotator Cuff Injuries
What Is Rotator Cuff Injuries?
What is a rotator cuff? Your rotator cuff is part of your shoulder joint . It's a group of muscles and tendons that holds the top part of your upper arm bone firmly in your shoulder socket. The rotator cuff keeps your shoulder stable when you move your arm in any direction. What are rotator cuff injuries? Rotator cuff injuries are common. Most of them are wear-and-tear injuries from doing the same arm movements over and over - especially reaching over your head. With time, the tissues in the rotator cuff break down, leading to these injuries: Tendinitis . The tendons in the rotator cuff connect your muscles to your shoulder bones.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Rotator Cuff Injuries (ICD-10 M15.1) is driven by articular hyaline cartilage in Rotator Cuff Injuries (M15.1: proteoglycan degradation); Cross-referenced with NIH MeSH (Rotator Cuff Injuries), specialists in Osteoarthritis, Gout & Joint Pain monitor hs-CRP & Erythrocyte in Rotator Cuff Injuries (M15.1: Sedimentation Rate) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • People over age 40. Most rotator cuff injuries are from the wear and tear of aging. By age 80, most adults have tears
- • Lie down, especially on the injured shoulder
- • Presentation of Rotator Cuff Injuries (M15.1): activity-related deep aching in Rotator Cuff Injuries (M15.1: joint pain in)
- • Secondary Rotator Cuff Injuries clinical sign: brief morning joint in Rotator Cuff Injuries (M15.1: stiffness)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Rotator Cuff Injuries Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M15.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Rotator Cuff Injuries (M15.1: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M15.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Rotator Cuff Injuries (M15.1: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M15.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Rotator Cuff Injuries M15.1] | Preserved joint-space width (M15.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Rotator Cuff Injuries
Treatment selection for Rotator Cuff Injuries depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rotator Cuff Injuries)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in: What a 287-Participant Study Found Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ-ADL arms. Arthritis & rheumatology (Hoboken, N.J.) • 2024-08-15 • Phase III Randomized Trial | N = 287 | 87/100 | PMID 38556921 ↗ |
| New Insights on Absence of Association Between Abatacept Exposure and Initial Infection in: What a 343-Participant Study Found In patients aged 2-17 years with pJIA, no evidence of association between higher levels of exposure to IV ABA or SC ABA and incidence of infection was observed. The Journal of rheumatology • 2021-07-15 • Phase III Randomized Trial | N = 343 | 87/100 | PMID 33452173 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of baricitinib in patients with moderate-to-severe autoimmune joint pain Treatment with baricitinib 4 mg or 2 mg demonstrated efficacy up to 6.5 years with maintained LDA/full symptom relief results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated. Rheumatology (Oxford, England) • 2024-10-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38258434 ↗ |
Rotator Cuff Injuries Patient Community & “People Like Me” Threads
Filter Rotator Cuff Injuries community threads and patient logs by age, biological sex, dosage, and treatment duration.